Akme Fintrade's board approved a preferential allotment of 1.3 crore shares, infusing ₹7.75 crore. The company also increased its authorized capital to ₹60 crore and proposed a higher borrowing limit of ₹1,200 crore. Changes in auditors were also noted.
Akme Fintrade Approves Capital Infusion and Enhanced Borrowing Powers
Akme Fintrade allotted 1.3 crore equity shares and increased authorized capital to ₹60 crore. The company also proposed enhancing its borrowing limit to ₹1,200 crore.
Reader Takeaway: Capital infusion and growth intent are positive, but AGM approval is a watch point.
What just happened
The Board of Akme Fintrade (India) Ltd has approved key financial and corporate actions. This includes a preferential allotment of 1.3 crore equity shares, effectively raising ₹7.75 crore. The allotment was made to Pushpa Jugraj Jain (30,00,000 shares for ₹2.50 crore) and Stellant Securities (India) Limited (1,00,00,000 shares for ₹5.25 crore).
Additionally, the company's authorized share capital has been increased from ₹50 crore to ₹60 crore. The Board also recommended enhancing the company's borrowing powers to ₹1,200 crore from the current limit, subject to shareholder approval.
Changes in auditors were also announced. Ms. Latika Jain resigned as Internal Auditor and Ms. Ankita Jain was appointed. M/s. Shyam S. Gupta & Associates are recommended as the new Statutory Auditors for a three-year term, replacing M/s. Valawat & Associates.
Why this matters
These decisions signal Akme Fintrade's focus on strengthening its financial base and preparing for future growth. The preferential allotment brings in fresh capital, bolstering the equity base. The increased authorized capital and significantly higher borrowing limit provide the company with greater financial flexibility to pursue expansion opportunities and manage its operations.
The backstory
Akme Fintrade (India) Ltd operates in the financial services sector. The company has been working on expanding its business and financial capacity. These recent approvals are part of a broader strategy to support its growth objectives and enhance its operational scale.
What changes now
The preferential allotment is complete, infusing capital into the company. The increase in authorized capital and the proposed enhancement of borrowing limits require shareholder approval at the upcoming 30th Annual General Meeting (AGM). The changes in auditors are also subject to this approval.
Risks to watch
The primary risk is the outcome of the 30th AGM. Shareholder approval is critical for the enhanced borrowing limit and the appointment of new statutory auditors. Until then, these decisions remain conditional.
Peer comparison
Financial services companies often raise capital through various means, including preferential allotments and rights issues, to fund growth. Increasing borrowing limits is a common strategy for NBFCs to leverage their balance sheets for expansion.
Context metrics (time-bound)
- Preferential Allotment Value: ₹7.75 crore (₹2.50 crore to Pushpa Jugraj Jain, ₹5.25 crore to Stellant Securities)
- New Authorized Capital: ₹60 crore (increased from ₹50 crore)
- Proposed Borrowing Limit: ₹1,200 crore (enhanced from a previous unspecified limit under Section 180(1)(c))
- Internal Auditor Term: April 1, 2026, to March 31, 2027
What to track next
Investors should closely watch the proceedings and outcomes of the 30th AGM. The approval of the enhanced borrowing limit and the appointment of the new statutory auditor will be key events to monitor.